Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market

Globalization and Health

Brian V Elliott²  Olive N Nakakeeto¹ 

[1] Independent health consultant, 387 Vi de Sales, F-01710, Thoiry, France;Independent pharmaceutical industry consultant, 18 Deerpark Lawn Castleknock, Dublin 15, Ireland

关键词: Market analysis;    Production cost;    AIDS;    HIV;    Antiretroviral drugs;   

Others  :  819374
DOI  :  10.1186/1744-8603-9-6

 received in 2012-10-07, accepted in 2013-02-11,  发布年份 2013

【 摘 要 】

Background

The price of antiretroviral drugs (ARVs) in low income countries declined steadily in recent years. This raises concerns about the commercial viability of the market of ARVs in low income countries.

Methods

Using 2 costing scenarios, we modeled the production cost of the most commonly used ARVs in low income countries in 2010 and 2012, and assessed whether, at the median price paid by low income countries, their manufacturers would still make profits. By interviews we consulted 11 generic manufacturers on the current state of the ARV market, and on what would be required to ensure their continued commitment to supply ARVs to low income countries.

Results

Using the lowest prices for active pharmaceutical ingredients (API) quoted to WHO, and applying published assumptions about the production cost of ARVs, our baseline estimate was that Indian generic manufacturers would have made profits on only 1 out of 13 formulations of ARVs in both 2010 and 2012, and publicly owned manufacturers would have made profits on 5 and 3 out of 13 formulations in 2010 and 2012, respectively. We needed to assume a 20% and a 40% lower API cost for our model to predict that publicly owned and Indian manufacturers, respectively, would make profits on the sale of the majority of their ARVs. Between 2010 and 2012, we estimate that - across the ARV portfolio - the gross profit on sales of ARVs to low income countries decreased with between 6% and 7% of their sales price. Generic manufacturers consider that current prices are unsustainable. They suggested amendments to the tender procedures, simplified regulatory procedures, improved forecasting, and simplification of the ARV guidelines as critical improvements to maintain a viable ARV market.

Conclusions

While recent price decreases indicate that there is still space for price reduction, our estimate that gross profit margin on sales decreased by 6 to 7% between 2010 and 2012 lends credibility to assertions by generic manufacturers that the ARV market in low income countries is under considerable price pressure. This might create problems for the quality and/or the continued supply of ARVs to low income countries.

【 授权许可】

   
2013 Nakakeeto and Elliott; licensee BioMed Central Ltd.

【 参考文献 】

• [1]UNAIDS: Global fact sheet. World AIDS Day 2012. 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_FactSheet_Global_en.pdf webcite. Accessed 25 January
• [2]UNAIDS: Ten targets. 2011 United Nations General Assembly Political Declaration on HIV/AIDS: Targets and elimination commitments. 2012. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2262_UNAIDS-ten-targets_en.pdf webcite. Accessed 14 September 2012
• [3]World Health Organization: The Global Price Reporting Mechanism for HIV, tuberculosis and malaria. 2013. http://apps.who.int/hiv/amds/price/hdd/ webcite. Database, accessed 14 January
• [4]UNITAID: HIV, tuberculosis and malaria medicines landscape. Progress report on emerging issues and potential opportunities to improve access. 2012. http://www.unitaid.eu/marketdynamics/medicines-landscape webcite. Accessed 14 September
• [5]World Health Organization: Global forecasts of antiretroviral demand 2012Ó2013: joint WHO/UNAIDS annual consultation with pharmaceutical companies. 2012. http://www.who.int/hiv/pub/meetingreports/consultation_pharmaceutical_companies/en/index.html webciteAccessed 14 September
• [6]World Health Organization: Annual 2010 Survey on ARV Use and Trends in Implementation of WHO 2010 ART Recommendations. 2012. http://www.who.int/hiv/amds/forecasting/en/index4.html webcite. Accessed 14 September
• [7]World Health Organization: Sources, quality and prices of active pharmaceutical ingredients of antiretroviral drugs: Results of a 2010 WHO survey. 2012. http://www.who.int/hiv/pub/amds/source_quality_price/en/index.html webcite. Accessed 14 September
• [8]World Health Organization: Sources, quality and prices of active pharmaceutical ingredients of antiretroviral drugs: Results of a 2012 WHO survey. 2012. http://www.who.int/hiv/pub/amds/api2012/en/index.html webcite. Accessed 14 September
• [9]Cipla: Seventy-Fifth Annual Report 2010Ó2011. 2012. http://www.cipla.com/corporateprofile/financial/pdf/cipla_ar_2010_11.pdf webcite. (page 33) Accessed 14 September
• [10]Ranbaxy: Annual report 2010. 2012. http://www.ranbaxy.com/investorinformation/annual_pr2010.aspx webcite. (page 65) Accessed 14 September
• [11]Strides Arcolab Ltd: Annual Report 2010. 2012. http://www.stridesarco.com/pdf/financial/annual/Strides_Financial_AR_2010.pdf webcite. (page 72) Accessed 14 September
• [12]Aurobindo Pharma Ltd: Annual Report 2010Ó2011. 2012. http://www.aurobindo.com/investor-relations/finance/annual-reports webcite. (page 66) Accessed 14 September
• [13]Pinheiro E, Vasan A, Kim JY, Lee E, Guimier JM, Perriens J: Examining the production costs of antiretroviral drugs. AIDS 2006, 20:1745-52.
• [14]International trade center: Market news service Ó Pharmaceutical Starting Materials. http://www.mnsonline.org/SectorSummary.aspx?idSector=da0f376b-bf86-4300-8ffb-7bae33b83b7c webcite
• [15]Khulekani Magunabe and Tamar Kahn: State to introduce three-in-one AIDS pill. In Business Day Live, 29 November 2012. 2013. http://www.bdlive.co.za/national/health/2012/11/29/state-to-introduce-three-in-one-aids-pill webciteAccessed 22 January
• [16]Reghu Balakrishnan: Margin woes compel Cipla to shift focus off HIV drugs. 2012. http://www.business-standard.com/india/news/margin-woes-compel-cipla-to-shift-focus-off-hiv-drugs/481812/ webcite. Accessed 3 Sept
• [17]Dennis C: WHO-prequalified Zimbabwean manufacturer Varichem stops producing ARVs (correction). 2012. http://www.essentialdrugs.org/edrug/archive/201203/msg00075.php webcite. Accessed 3 Sept
• [18]Varichem stops producing ARVs. 2012. http://www.herald.co.zw/index.php?option=com_content&view=article&id=35727:v webciteAccessed 3 Sept
• [19]Médecins Sans Frontières: Untangling the Web of antiretroviral price reductions. 15th edition. 2012. http://utw.msfaccess.org/downloads/documents webcite. Accessed 14 September
• [20]WHO and UNAIDS: The treatment 2.0 framework for action: catalysing the next phase of treatment, care and support. 2013. http://www.who.int/hiv/pub/arv/treatment/en/index.html webcite. Accessed 6 January